drugset / Trial / NCT02809573
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chidamide in a range of doses combined with CHOP in fixed dose in patients with newly diagnosed peripheral T-cell lymphoma.
Timeline
- Start
- 2016-08-11
- Primary completion
- 2019-01-08
- Completion
- 2019-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | — | Oral |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 100 mg | Oral |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |